[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100471048":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":60,"collaborators":62,"id":66,"slug":20,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":20,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":20,"enrollmentInfo":74,"targetDuration":20,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":85,"overallStatus":43,"whyStopped":20,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"UNC Lineberger Comprehensive Cancer Center","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Single Arm","This is a single arm study. All participants will receive same interventions.",[12,13,14],"Other: Urine HPV testing","Other: Self-collected cervicovaginal specimen","Other: Provider-collected cervical samples",[16,21,25],{"type":6,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"Urine HPV testing","Human papillomavirus (HPV) testing in urine sample.",[9],null,{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":20},"Self-collected cervicovaginal specimen","Human papillomavirus (HPV) testing in self-collected cervicovaginal specimen sample.",[9],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":20},"Provider-collected cervical samples","Human papillomavirus (HPV) testing in healthcare provider collected cervicovaginal specimen sample.",[9],[30],{"name":31,"affiliation":32,"role":33},"Carla Chibwesha, MD, MSc","Division of Global Women's Health Department of Obstetrics and Gynecology, UNC Chapel Hill, NC","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":20,"email":39},"Cheryl Hendrickson","CONTACT","919-843-2541","cheryl_hendrickson@med.unc.edu",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Clinical HIV Research Unit Temba Lethu Wing Helen Joseph Hospital","RECRUITING","Westdene","Johannesburg","2092","South Africa",{"type":49,"coordinates":50},"Point",[51,52],27.98757,-26.17533,{"lat":52,"lon":51},[55,59],{"name":56,"role":37,"phone":57,"phoneExt":20,"email":58},"Sibusisiwe Luvuno","+27-11-276-8800","sluvuno@witshealth.co.za",{"name":31,"role":33,"phone":20,"phoneExt":20,"email":20},{"type":61,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[63],{"name":64,"class":65},"National Cancer Institute (NCI)","NIH","100471048",false,"NCT05413798","Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa","Clinical Performance Validation of Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa","Inclusion Criteria:\n\nIn order to participate in this study a subject must meet all of the eligibility criteria outlined below.\n\n1. Confirmed HIV-1 infection\n2. Age 25 years and older.\n3. Be willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Pregnant or intend to become pregnant within 90 days of enrollment\n2. Have been screened for cervical cancer within the preceding year (365 days)\n3. Have an active sexually transmitted infection (STI; women may participate once treated)\n4. Have a surgically absent cervix\n5. Have a history of cervical cancer\n6. have been vaccinated against HPV.","FEMALE","25 Years",{"count":75,"type":76},300,"ESTIMATED","INTERVENTIONAL",[79],"NA","The purpose of this study explores the usefulness of urine samples for cervical cancer screening in human immunodeficiency virus (HIV)-infected women.\n\nCervical cancer occurs when women are infected with the human papillomavirus (HPV), which can cause changes in the cells that lead to cervical precancer and, eventually, cervical cancer if untreated. However, urine HPV testing has not been well validated low- and middle-income country settings, with no data available to guide its use in HIV-infected women.",[82,83,84],"Cervical Cancer","CIN2","CIN3",[86,87,88,89],"cervical cancer","HPV","urine test","HIV","2026-06-29",{"date":92,"type":93},"2026-07-01","ACTUAL",{"date":95,"type":93},"2023-05-11",{"date":97,"type":76},"2026-08",{"name":5,"class":6},1]